instructiors): The broad objective of the Administrative Core is to provide multiple levels of program management support to the project and core investigators. Dr. Segal, as program director, will be responsible for all aspects of program management. To facilitate communication, coordination and planning among the projects and the INP Core, Dr. Segal will be assisted by a scientific program coordinator. Dr. Segal will also be aided by the Cancer Biology Business Office to assist her in the fiscal management of the award. The Administrative Core has three specific aims:
Aim one is to provide effective communication, coordination and planning for the program. Dr. Segal and the scientific program coordinator will schedule and facilitate monthly research -in- progress meetings for project and core investigators. The internal advisory board will be invited to this meeting on a semi-annual basis, and the external advisor will be invited to attend yearly, to provide their fresh perspectives and guidance. Following these advisory meetings, Dr. Segal and the program coordinator will synthesize the evaluations and recommendations from the advisory board and distribute them to all project and core investigators.
Aim two is to assist the Dr. Segal with fiscal management of the award. This includes processing award notices from the NIH, managing project budgets, and assisting in the preparation of annual progress reports to the NIH. Our Business Office is staffed with grants management specialists who concentrate on either pre-award or post-award aspects of research awards.
Aim three is to provide clerical support to Dr. Segal for tracking annual renewals of animal and human protocols, manuscript preparation, traveling and scheduling as it pertains to the program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142536-03
Application #
8450186
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
3
Fiscal Year
2013
Total Cost
$228,444
Indirect Cost
$118,704
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Ilic, Nina; Birsoy, K?vanç; Aguirre, Andrew J et al. (2017) PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A 114:E3434-E3443
Zhou, Jing; Tien, An-Chi; Alberta, John A et al. (2017) A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep 18:3167-3177
Zhang, Jing; Gao, Xueliang; Schmit, Fabienne et al. (2017) CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20:549-557
Ramkissoon, Shakti H; Bandopadhayay, Pratiti; Hwang, Jaeho et al. (2017) Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol 19:986-996
Sun, Yu; Alberta, John A; Pilarz, Catherine et al. (2017) A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol 19:774-785
Zhao, Xuesong; Pak, Ekaterina; Ornell, Kimberly J et al. (2017) A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors. Cancer Discov 7:1436-1449
Ni, Jing; Xie, Shaozhen; Ramkissoon, Shakti H et al. (2017) Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19:22-30
Pak, Ekaterina; Segal, Rosalind A (2016) Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell 38:333-44
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167

Showing the most recent 10 out of 59 publications